tiprankstipranks
Trending News
More News >
Atara Biotherapeutics (ATRA)
NASDAQ:ATRA
US Market

Atara Biotherapeutics (ATRA) Stock Forecast & Price Target

Compare
1,146 Followers
See the Price Targets and Ratings of:

ATRA Analyst Ratings

Moderate Buy
3Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Atara
Biotherapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ATRA Stock 12 Month Forecast

Average Price Target

$10.00
▲(18.76%Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. The average price target is $10.00 with a high forecast of $17.00 and a low forecast of $3.00. The average price target represents a 18.76% change from the last price of $8.42.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jul<br/>2024","9":"Dec<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.56,8.286153846153846,9.012307692307692,9.73846153846154,10.464615384615385,11.19076923076923,11.916923076923077,12.643076923076922,13.36923076923077,14.095384615384617,14.821538461538463,15.547692307692309,16.273846153846154,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.56,7.747692307692307,7.935384615384615,8.123076923076923,8.31076923076923,8.498461538461537,8.686153846153847,8.873846153846154,9.061538461538461,9.249230769230769,9.436923076923076,9.624615384615385,9.812307692307693,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.56,7.209230769230769,6.858461538461539,6.507692307692308,6.156923076923077,5.806153846153846,5.455384615384615,5.104615384615385,4.753846153846154,4.403076923076923,4.052307692307693,3.701538461538462,3.350769230769231,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.84,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.84,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.75,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.27,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.12,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.11,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1719792000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$17.00Average Price Target$10.00Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ATRA
TipRanks AITipRanks
Not Ranked
TipRanks
$8
Hold
-4.99%
Downside
Reiterated
06/05/25
Atara Biotherapeutics faces significant financial challenges with high leverage and negative equity, which are major concerns. Positive technical indicators and recent corporate events, such as strategic restructuring and regulatory progress, provide some optimism, but the overall outlook remains cautious given the financial instability.
Canaccord Genuity Analyst forecast on ATRA
John NewmanCanaccord Genuity
Canaccord Genuity
$17
Buy
101.90%
Upside
Reiterated
05/15/25
Buy Rating for Atara Biotherapeutics: Strategic Focus and Financial Positioning Ahead of Key FDA Meeting
Stifel Nicolaus Analyst forecast on ATRA
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$3
Hold
-64.37%
Downside
Reiterated
03/11/25
Stifel Nicolaus Remains a Hold on Atara Biotherapeutics (ATRA)
TD Cowen Analyst forecast on ATRA
Phil NadeauTD Cowen
TD Cowen
Buy
Reiterated
03/09/25
Atara Biotherapeutics (ATRA) Receives a Buy from TD CowenWe see this as resolvable and ultimately expect BLA resubmission/approval. A regulatory update is expected in Q2:25. Due to current capital constraints, ATRA has paused the '3219/'3431 CAR-T programs and cut headcount by 50%.
H.C. Wainwright Analyst forecast on ATRA
Robert BurnsH.C. Wainwright
H.C. Wainwright
Hold
Reiterated
01/28/25
Atara Biotherapeutics: Workforce Reductions and Regulatory Challenges Lead to Hold RatingWe previously valued Atara using a discounted cash flow (DCF)-driven valuation methodology, which ascribed a 95% probability of approval to tab-cel in 10% probability of approval to ATA3219.
Rodman & Renshaw Analyst forecast on ATRA
Anthony ButlerRodman & Renshaw
Rodman & Renshaw
$25$7
Hold
-16.86%
Downside
Downgraded
01/21/25
Atara Biotherapeutics downgraded to Neutral from Buy at Rodman & RenshawAtara Biotherapeutics downgraded to Neutral from Buy at Rodman & Renshaw
Mizuho Securities Analyst forecast on ATRA
Salim SyedMizuho Securities
Mizuho Securities
$25$18
Buy
113.78%
Upside
Upgraded
08/16/24
Atara Biotherapeutics upgraded to Outperform from Neutral at MizuhoAtara Biotherapeutics upgraded to Outperform from Neutral at Mizuho
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ATRA
TipRanks AITipRanks
Not Ranked
TipRanks
$8
Hold
-4.99%
Downside
Reiterated
06/05/25
Atara Biotherapeutics faces significant financial challenges with high leverage and negative equity, which are major concerns. Positive technical indicators and recent corporate events, such as strategic restructuring and regulatory progress, provide some optimism, but the overall outlook remains cautious given the financial instability.
Canaccord Genuity Analyst forecast on ATRA
John NewmanCanaccord Genuity
Canaccord Genuity
$17
Buy
101.90%
Upside
Reiterated
05/15/25
Buy Rating for Atara Biotherapeutics: Strategic Focus and Financial Positioning Ahead of Key FDA Meeting
Stifel Nicolaus Analyst forecast on ATRA
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$3
Hold
-64.37%
Downside
Reiterated
03/11/25
Stifel Nicolaus Remains a Hold on Atara Biotherapeutics (ATRA)
TD Cowen Analyst forecast on ATRA
Phil NadeauTD Cowen
TD Cowen
Buy
Reiterated
03/09/25
Atara Biotherapeutics (ATRA) Receives a Buy from TD CowenWe see this as resolvable and ultimately expect BLA resubmission/approval. A regulatory update is expected in Q2:25. Due to current capital constraints, ATRA has paused the '3219/'3431 CAR-T programs and cut headcount by 50%.
H.C. Wainwright Analyst forecast on ATRA
Robert BurnsH.C. Wainwright
H.C. Wainwright
Hold
Reiterated
01/28/25
Atara Biotherapeutics: Workforce Reductions and Regulatory Challenges Lead to Hold RatingWe previously valued Atara using a discounted cash flow (DCF)-driven valuation methodology, which ascribed a 95% probability of approval to tab-cel in 10% probability of approval to ATA3219.
Rodman & Renshaw Analyst forecast on ATRA
Anthony ButlerRodman & Renshaw
Rodman & Renshaw
$25$7
Hold
-16.86%
Downside
Downgraded
01/21/25
Atara Biotherapeutics downgraded to Neutral from Buy at Rodman & RenshawAtara Biotherapeutics downgraded to Neutral from Buy at Rodman & Renshaw
Mizuho Securities Analyst forecast on ATRA
Salim SyedMizuho Securities
Mizuho Securities
$25$18
Buy
113.78%
Upside
Upgraded
08/16/24
Atara Biotherapeutics upgraded to Outperform from Neutral at MizuhoAtara Biotherapeutics upgraded to Outperform from Neutral at Mizuho
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Atara Biotherapeutics

1 Month
xxx
Success Rate
17/41 ratings generated profit
41%
Average Return
+0.04%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 41.46% of your transactions generating a profit, with an average return of +0.04% per trade.
3 Months
xxx
Success Rate
19/41 ratings generated profit
46%
Average Return
+5.06%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 46.34% of your transactions generating a profit, with an average return of +5.06% per trade.
1 Year
John NewmanCanaccord Genuity
Success Rate
18/41 ratings generated profit
44%
Average Return
-7.43%
reiterated a buy rating 23 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 43.90% of your transactions generating a profit, with an average return of -7.43% per trade.
2 Years
xxx
Success Rate
6/41 ratings generated profit
15%
Average Return
-47.72%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 14.63% of your transactions generating a profit, with an average return of -47.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ATRA Analyst Recommendation Trends

Rating
Nov 24
Dec 24
Jan 25
Mar 25
May 25
Strong Buy
2
2
1
2
3
Buy
2
1
1
0
0
Hold
3
4
6
6
5
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
7
8
8
8
In the current month, ATRA has received 3 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ATRA average Analyst price target in the past 3 months is 10.00.
Each month's total comprises the sum of three months' worth of ratings.

ATRA Financial Forecast

ATRA Earnings Forecast

Next quarter’s earnings estimate for ATRA is -$0.24 with a range of -$0.60 to $0.19. The previous quarter’s EPS was $3.50. ATRA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ATRA has Outperformed its overall industry.
Next quarter’s earnings estimate for ATRA is -$0.24 with a range of -$0.60 to $0.19. The previous quarter’s EPS was $3.50. ATRA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ATRA has Outperformed its overall industry.

ATRA Sales Forecast

Next quarter’s sales forecast for ATRA is $5.57M with a range of $0.00 to $14.70M. The previous quarter’s sales results were $98.15M. ATRA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year ATRA has Outperformed its overall industry.
Next quarter’s sales forecast for ATRA is $5.57M with a range of $0.00 to $14.70M. The previous quarter’s sales results were $98.15M. ATRA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year ATRA has Outperformed its overall industry.

ATRA Stock Forecast FAQ

What is ATRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Atara Biotherapeutics’s 12-month average price target is 10.00.
    What is ATRA’s upside potential, based on the analysts’ average price target?
    Atara Biotherapeutics has 18.76% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ATRA a Buy, Sell or Hold?
          Atara Biotherapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Atara Biotherapeutics’s price target?
            The average price target for Atara Biotherapeutics is 10.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $17.00 ,the lowest forecast is $3.00. The average price target represents 18.76% Increase from the current price of $8.42.
              What do analysts say about Atara Biotherapeutics?
              Atara Biotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of ATRA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis